The transthyretin amyloid cardiomyopathy treatment market involves medicinal products intended to slow down or halt ATTR-CM, a rare and progressive heart disease caused by mutated transthyretin protein deposits in heart tissues. Currently available drugs like tafamidis and inotersen help stabilize transthyretin tetramers and prevent amyloid formation. Gene silencing therapies aim to reduce transthyretin production and break down existing amyloid deposits, enabling symptom management and improved quality of life.
The global transthyretin amyloid cardiomyopathy treatment market is estimated to be valued at US$ 1943.69 billion in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the transthyretin amyloid cardiomyopathy treatment market include DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin,PMD Beauty, Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC. (HydraFacial) among others.
The growing prevalence of ATTR-CM and limited treatment alternatives available have spurred the demand for novel therapies. BioMarin Pharmaceutical, Alnylam Pharmaceuticals, and Eidos Therapeutics are some key players involved in research and clinical trials of gene silencing drugs for ATTR-CM.
Moreover, the market players are expanding their geographical presence through collaboration with regional healthcare systems. For instance, Pfizer obtained approval for tafamidis in major European markets in 2020 to benefit more ATTR-CM patients globally.
Market key trends
Personalized medicine approach is gaining traction in Transthyretin Amyloid Cardiomyopathy Treatment Market Growth with therapies tailored to individual patient characteristics like phenotypic expression, disease stage, age, and genetic mutation. Based on disease manifestation and progression rate, treatment selection, dosage, and monitoring are personalized. This trend allows optimizing outcomes while minimizing adverse effects. Moreover, combination therapies combining gene silencing drugs with stabilizers are being explored to achieve synergistic effects for more comprehensive disease management.
Porter’s Analysis
Threat of new entrants: Low barriers to enter the market such as requirements for manufacturing facilities or distribution channels. However, established players have significant brand recognition and resources to maintain their market position.
Bargaining power of buyers: Buyers have high bargaining power due to presence of many suppliers and substitutes in the market. Buyers can negotiate on price and demand high quality at lower costs.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to presence of many substitutes and ease of forward integration by manufacturers.
Threat of new substitutes: Threat of substitutes is moderate as there are several treatment alternatives available for cardiomyopathy.
Competitive rivalry: Intense competition among existing players to gain higher market share. Players compete on product quality, brand, innovation and price.
Geographical Regions
North America holds the largest share of the transthyretin amyloid cardiomyopathy treatment market owing to increasing awareness, high healthcare spending and presence of major market players. The region accounted for about 35% of global market share in 2024.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period due to rising geriatric population, improving healthcare infrastructure and increasing disposable incomes. Countries like China and India are expected to drive the market in the region supported by growing patient pool, availability of low-cost generic drugs and rising medical tourism.
Geographical Regions
The transthyretin amyloid cardiomyopathy treatment market in Europe is majorly concentrated in Western European countries like Germany, UK, France and Italy. Presence of advanced healthcare facilities, favorable reimbursement policies and growing awareness for rare diseases are fueling market growth. However, austerity measures and healthcare budget cuts in some nations may restrain the market to some extent.
The market in Latin America and Middle East & Africa is still at a nascent stage due to low accessibility to diagnostics and drugs. However, increasing collaboration of global players with local stakeholders is expected to boost market penetration in these regions over the coming years. High undiagnosed patient population indicates future growth opportunities.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it